Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26848345 | 0.93 | PLA2G2A (0.38) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL26757374 | 0.90 | LPAR3 (0.40) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL16559185 | 0.89 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL21257334 | 0.89 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL213020 | 0.89 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL16559186 | 0.89 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL14614344 | 0.88 | LPAR3 (0.42) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL21553512 | 0.83 | SAT1 (0.41) | LPAR3LPAR2LPAR1 | |
| SCHEMBL1900350 | 0.82 | LPAR3 (0.52) | LPAR3LPAR2LPAR1 | |
| SCHEMBL16559184 | 0.82 | LPAR3 (0.39) | LPAR3LPAR2LPAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230366885-A1 | DNA CONSTRUCTS, RECOMBINANT CELLS COMPRISING THEREOF, BACTERIAL PROBES, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-16 | — | — | US | disclosed |
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639929-B2 | Universal histidine-tag binding compounds and methods of use thereof as fluorescent probes and sensors | HCLS1, PHF6, PHPT1 | LPAR3 4564/4885LPAR2 4740/4885LPAR1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.